306SC, Director / Associate Director, Program Management (Clinical Translation)

Job Code 306SC

Description

Fate is seeking an experienced Director / Associate Director, Program Management to manage clinical translational initiatives in the development and potential commercialization of Fate’s iProduct portfolio consisting of off-the-shelf cellular immunotherapeutics. The successful candidate is responsible for owning and achieving interim and final deliverables in infrastructure/translational research and process development to support the product development life cycle, according to the time, quality/scope and corporate objectives. This individual will in part direct cross-functional teams to accomplish various tasks and will proactively identify, resolve/mitigate and escalate risks and/or issues. The Director / Associate Director, Program Management adheres to Fate Therapeutics standard procedures and processes. This individual may be required to manage large and/or particularly complex, multifaceted projects or programs and may provide oversight to other members of the project management group. This is a full-time position located at our corporate headquarters in San Diego, CA reporting to the SVP, Clinical Translation.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 306SC.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.